Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COGNITION THERAPEUTICS INCCGTX · Entity 6792 | Director | June 17, 2026 | June 22, 2026 |
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | Director · Chief Executive Officer | August 31, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COGNITION THERAPEUTICS INC
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 73,500 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 25,000 · Balance 73,500 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 17, 2027 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 17, 2027 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.
IONIS PHARMACEUTICALS INC
Report date August 31, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 242,760 |
Reported balance
After 2026-08-31 transaction · row 1
1 source rowRow 1 · 2026-08-31 · Other · Acquired 98 · Balance 242,760 F1: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 15, 2020 Filed Jan 17, 2020 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Tax withholdingCommon Stock | 7,563 | $62.06 | $469,359.78 |
DisclosureSEC source: 0000874015-20-000035 · edgar.xml · nonDerivative · entry 2 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,643 F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 19,921 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000035 · edgar.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. Read SEC document |
| January 02, 2020 Filed Jan 4, 2020 00:04 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantEmployee Stock Option (right to buy) · Derivative | 158,659 | $0.00 Strike: $60.89 | $0.00 |
DisclosureSEC source: 0000874015-20-000014 · edgar.xml · derivative · entry 2 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,659 Underlying: Common Stock · 158,659 shares Expires 2027-01-01 F2 · derivative.exercise_date: Grant on 01/02/2020 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2020. 25% of the shares subject to the option will vest and become exercisable on 01/02/2021. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years. Read SEC document |
| January 02, 2020 Filed Jan 4, 2020 00:04 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 173 | $60.25 | $10,423.25 |
DisclosureSEC source: 0000874015-20-000014 · edgar.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,285 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 10/7/2019. F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 10/7/2019. Read SEC document |
| January 02, 2020 Filed Jan 31, 2020 21:55 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantEmployee Stock Option (right to buy) · Derivative | 148,454 | $0.00 Strike: $60.89 | $0.00 |
DisclosureSEC source: 0000874015-20-000043 · edgar.xml · derivative · entry 1 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,454 Underlying: Common Stock · 148,454 shares Expires 2027-01-01 F2 · shares: The original Form 4 filed on January 6, 2020 reported a grant of 158,659 stock options to the reporting person which has been revised by this amendment to reflect the amount of the actual award granted to Dr. Monia. F1 · derivative.exercise_date: Grant on 01/02/2020 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2020. 25% of the shares subject to the option will vest and become exercisable on 01/02/2021. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years. Read SEC document |
| November 20, 2019 Filed Nov 21, 2019 23:38 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 5,776 | $60.01 | $346,617.76 |
DisclosureSEC source: 0000874015-19-000135 · edgar.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · Director · COO & SVP, Translational Med 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,458 F1 · kind: The sale of shares owned was made pursuant to a 10b5-1 Trading Plan adopted by the reporting person on 10/7/2019. F1 · shares: The sale of shares owned was made pursuant to a 10b5-1 Trading Plan adopted by the reporting person on 10/7/2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.01, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 00:50 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 210 | $66.40 | $13,944.00 |
DisclosureSEC source: 0000874015-19-000089 · edgar.xml · nonDerivative · entry 2 Monia Brett P · CIK 0001537529 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,234 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 07/01/2014. F2 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 07/01/2014. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 00:50 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 173 | $45.70 | $7,906.88 |
DisclosureSEC source: 0000874015-19-000089 · edgar.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,444 F1 · kind: Reporting 173 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2019. These 173 shares may not be sold until January 2, 2020. F1 · shares: Reporting 173 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2019. These 173 shares may not be sold until January 2, 2020. Read SEC document |
| January 15, 2019 Filed Jan 18, 2019 00:34 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 10,006 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-19-000024 · edgar.xml · derivative · entry 4 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,280 Underlying: Common Stock · 10,006 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2019 Filed Jan 18, 2019 00:34 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Units · Derivative | 45,728 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-19-000024 · edgar.xml · derivative · entry 3 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,728 Underlying: Common Stock · 45,728 shares Expires not disclosed F3 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2019 Filed Jan 18, 2019 00:34 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Tax withholdingCommon Stock | 3,572 | $58.26 | $208,104.72 |
DisclosureSEC source: 0000874015-19-000024 · edgar.xml · nonDerivative · entry 2 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,275 F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. Read SEC document |
| January 15, 2019 Filed Jan 18, 2019 00:34 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 10,006 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-19-000024 · edgar.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 00:42 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantEmployee Stock Option (right to buy) · Derivative | 102,900 | $0.00 Strike: $53.77 | $0.00 |
DisclosureSEC source: 0000874015-19-000009 · edgar.xml · derivative · entry 3 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,900 Underlying: Common Stock · 102,900 shares Expires 2026-01-01 F2 · derivative.exercise_date: Grant of 01/02/2019 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 01/02/2020. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments over the next 3 years. Following this transaction, the option was exercisable as to 0 on 01/02/2019. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 00:42 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 214 | $53.50 | $11,449.00 |
DisclosureSEC source: 0000874015-19-000009 · edgar.xml · nonDerivative · entry 2 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,837 F3 · kind: The Sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 07/01/2014. F3 · shares: The Sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 07/01/2014. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 00:42 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 210 | $36.45 | $7,654.08 |
DisclosureSEC source: 0000874015-19-000009 · edgar.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,051 F1 · kind: Reporting shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2019. These shares may not be sold until July 2, 2019. F1 · shares: Reporting shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2019. These shares may not be sold until July 2, 2019. Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 01:01 UTC | IONIS PHARMACEUTICALS INC IONIS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 34,000 | $0.00 Strike: $14.69 | $0.00 |
DisclosureSEC source: 0000874015-18-000130 · edgar.xml · derivative · entry 3 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,000 shares Expires 2020-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 01:01 UTC | IONIS PHARMACEUTICALS INC IONIS · Entity 1182 | SaleCommon Stock | 34,000 | $55.00 | $1,870,057.80 |
DisclosureSEC source: 0000874015-18-000130 · edgar.xml · nonDerivative · entry 2 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,841 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 05/11/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 05/11/2018. F2 · price: The price reported in Column 4 is a weighted average price. These share were sold in multiple transactions at prices ranging from $55.00 to $55.08, inclusiveThe reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 01:01 UTC | IONIS PHARMACEUTICALS INC IONIS · Entity 1182 | Exercise / conversionCommon Stock | 34,000 | $14.69 | $499,460.00 |
DisclosureSEC source: 0000874015-18-000130 · edgar.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 05/11/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 05/11/2018. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 20:49 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $7.21 | $0.00 |
DisclosureSEC source: 0000874015-18-000109 · edgar.xml · derivative · entry 6 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2018-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 20:49 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 8,993 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-18-000109 · edgar.xml · derivative · entry 5 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,993 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 20:49 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 7,500 | $54.00 | $405,000.00 |
DisclosureSEC source: 0000874015-18-000109 · edgar.xml · nonDerivative · entry 4 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,841 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 5/11/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 5/11/2018. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 20:49 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 7,500 | $7.21 | $54,075.00 |
DisclosureSEC source: 0000874015-18-000109 · edgar.xml · nonDerivative · entry 3 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 5/11/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 5/11/2018. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 20:49 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 8,993 | $54.00 | $485,622.00 |
DisclosureSEC source: 0000874015-18-000109 · edgar.xml · nonDerivative · entry 2 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,841 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 5/11/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 5/11/2018. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 20:49 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 8,993 | $7.25 | $65,199.25 |
DisclosureSEC source: 0000874015-18-000109 · edgar.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 5/11/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 5/11/2018. Read SEC document |
| July 24, 2018 Filed Jul 25, 2018 23:19 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 156 | $47.03 | $7,336.68 |
DisclosureSEC source: 0000874015-18-000103 · edgar.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,841 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 7/1/2014. F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 7/1/2014. Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 19:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 214 | $35.42 | $7,579.77 |
DisclosureSEC source: 0000874015-18-000091 · edgar.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,997 F1 · kind: Reporting 214 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2018. These 214 shares may not be sold until January 2, 2019. F1 · shares: Reporting 214 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2018. These 214 shares may not be sold until January 2, 2019. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 02:21 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 2,821 | $51.76 | $146,014.96 |
DisclosureSEC source: 0000874015-18-000017 · edgar.xml · nonDerivative · entry 2 Monia Brett P · CIK 0001537529 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,783 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.759 to $51.761, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| January 15, 2018 Filed Jan 18, 2018 02:21 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 6,985 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000017 · edgar.xml · derivative · entry 6 Monia Brett P · CIK 0001537529 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,703 Underlying: Common Stock · 6,985 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F6 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F6 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2018 Filed Jan 18, 2018 02:21 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Units · Derivative | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000017 · edgar.xml · derivative · entry 5 Monia Brett P · CIK 0001537529 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires not disclosed F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F7 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. F6 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F6 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2018 Filed Jan 18, 2018 02:21 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Units · Derivative | 12,916 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000017 · edgar.xml · derivative · entry 4 Monia Brett P · CIK 0001537529 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,916 Underlying: Common Stock · 12,916 shares Expires not disclosed F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F7 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. F6 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F6 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2018 Filed Jan 18, 2018 02:21 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 6,985 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000017 · edgar.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| January 14, 2018 Filed Jan 18, 2018 02:21 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $53.22 | $0.00 |
DisclosureSEC source: 0000874015-18-000017 · edgar.xml · derivative · entry 3 Monia Brett P · CIK 0001537529 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2025-01-13 F4 · derivative.exercise_date: Grant of 1/14/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/14/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 7,500 shares per year. Following this transaction, the option was exercisable as to 0 on 1/14/2018. F4 · derivative.expiration_date: Grant of 1/14/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/14/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 7,500 shares per year. Following this transaction, the option was exercisable as to 0 on 1/14/2018. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 01:49 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantEmployee Stock Option (right to buy) · Derivative | 58,125 | $0.00 Strike: $49.25 | $0.00 |
DisclosureSEC source: 0000874015-18-000007 · edgar.xml · derivative · entry 3 Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,125 Underlying: Common Stock · 58,125 shares Expires 2025-01-01 F2 · derivative.exercise_date: Grant of 1/2/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 14,531 shares per year. Following this transaction, the option was exercisable as to 0 on 1/2/2018. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 01:49 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 163 | $50.00 | $8,150.00 |
DisclosureSEC source: 0000874015-18-000007 · edgar.xml · nonDerivative · entry 2 Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,619 F3 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 7/31/2014. F3 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 7/31/2014. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 01:49 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 156 | $42.76 | $6,669.78 |
DisclosureSEC source: 0000874015-18-000007 · edgar.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,782 F1 · kind: Reporting 156 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 156 shares may not be sold until July 2, 2018. F1 · shares: Reporting 156 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 156 shares may not be sold until July 2, 2018. Read SEC document |
| July 03, 2017 Filed Jul 3, 2017 21:38 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 309 | $51.35 | $15,867.15 |
DisclosureSEC source: 0000874015-17-000049 · edgar.xml · nonDerivative · entry 2 Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,626 F2 · kind: The sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 7/1/2014. F2 · shares: The sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 7/1/2014. Read SEC document |
| July 01, 2017 Filed Jul 3, 2017 21:38 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 163 | $40.66 | $6,626.85 |
DisclosureSEC source: 0000874015-17-000049 · edgar.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,935 F1 · kind: Reporting 163 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2017. These 163 shares may not be sold until January 2, 2018. F1 · shares: Reporting 163 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2017. These 163 shares may not be sold until January 2, 2018. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:38 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 623 | $46.29 | $28,838.67 |
DisclosureSEC source: 0000874015-17-000016 · edgar.xml · nonDerivative · entry 8 Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,772 F8 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2016. F8 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2016. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:38 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 593 | $46.29 | $27,450.56 |
DisclosureSEC source: 0000874015-17-000016 · edgar.xml · nonDerivative · entry 6 Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,801 F6 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2015. F6 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2015. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:38 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 733 | $46.29 | $33,931.30 |
DisclosureSEC source: 0000874015-17-000016 · edgar.xml · nonDerivative · entry 4 Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,876 F4 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2014. F4 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2014. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:38 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 553 | $46.29 | $25,598.37 |
DisclosureSEC source: 0000874015-17-000016 · edgar.xml · nonDerivative · entry 2 Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,734 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 30, 2013. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 30, 2013. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:38 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 1,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000016 · edgar.xml · derivative · entry 13 Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,779 Underlying: Common Stock · 1,594 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F8 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2016. F11 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F11 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:38 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 1,518 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000016 · edgar.xml · derivative · entry 12 Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,034 Underlying: Common Stock · 1,518 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F6 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2015. F11 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F11 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:38 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000016 · edgar.xml · derivative · entry 11 Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 Underlying: Common Stock · 1,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2014. F11 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F11 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:38 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 1,415 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000016 · edgar.xml · derivative · entry 10 Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,415 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 30, 2013. F11 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F11 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:38 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Units · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000016 · edgar.xml · derivative · entry 9 Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires not disclosed F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F10 · derivative.exercise_date: Grant 1/15/2017 to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on January 15, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2021. The RSU is vested as to 0 shares on January 15, 2017. F10 · derivative.expiration_date: Grant 1/15/2017 to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on January 15, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2021. The RSU is vested as to 0 shares on January 15, 2017. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:38 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000016 · edgar.xml · nonDerivative · entry 7 Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2016. F7 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2016. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:38 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,518 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000016 · edgar.xml · nonDerivative · entry 5 Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2015. F5 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2015. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:38 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000016 · edgar.xml · nonDerivative · entry 3 Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,609 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2014. F3 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2014. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:38 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,415 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000016 · edgar.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 30, 2013. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 30, 2013. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.